Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

JERUSALEM, Dec. 16, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML). The early results show that BL-8040, as a stand-alone therapy and in combination with high-dose Cytarabine (Ara-C), is safe at all doses tested to date, and triggers substantial mobilization of cancer cells from the bone marrow to the peripheral blood, thereby increasing the vulnerability of the cells to chemotherapy treatment. In addition, signs of robust apoptosis (cell death) of cancer cells were observed following administration of the higher doses tested to date. The study has not yet reached the highest planned doses, suggesting that a strengthening of BL-8040's effects may be observed in future dosing cohorts.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769 )

The Phase 2 trial is a multicenter, open-label study under an IND, and is designed to evaluate the safety and efficacy of repeated escalating doses of BL-8040 in adult patients with relapsed or refractory AML. The primary endpoints of the study are to assess the safety and tolerability of BL-8040. Secondary endpoints include the pharmacokinetic profile of the drug and an efficacy evaluation, indicated by the extent of mobilization of cancer cells from the bone marrow to the peripheral blood, the level of cancer cell death (apoptosis) and clinical responses.

Eight patients have already been enrolled in the study, out of a total expected enrollment of up to 50 patients at eight clinical sites in the U.S. and Isr
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... research analysis approaches are evolving across industry sectors ... are now examining better ways to engage with ... how consumers inform themselves and make critical purchasing ... by benchmarking firm, Best Practices, LLC, one area ...
(Date:7/11/2014)... Research and Markets has announced ... X-ray Film Industry Report 2014" report to their ... Global And Chinese Medical X-Ray Film Industry Report ... current state of the Global medical X-ray film industry ... report provides a basic overview of the industry including ...
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... BioTrends Research Group, Inc. recently published its ... is based on online survey ... radiologists and interventional nephrologists). It provides an in-depth view ... patterns related to both vascular access placement and maintenance. ...
... Aug. 24 Sunridge International (OTC Bulletin Board: ... next month to have meetings with key brokers and funds. ... to our company,s technology, and to facilitate funding for Sunridge ... "Now is a good time for this project," states G. ...
Cached Medicine Technology:Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market 2
(Date:7/14/2014)... Botanica Day Spa announced last month that their ... the day spa in down town Clearwater, FL on ... refreshments will be served as clients are invited to ... and great deals on spa services, including the ... (also known as “facial shaving”) is a simple and ...
(Date:7/14/2014)... 2014 (HealthDay News) -- Eye tests could be used ... disease, two new studies suggest. In one study, ... eye test found a significant association between levels of ... levels of the plaques in the brain. Beta-amyloid plaques ... This type of eye test could be used in ...
(Date:7/14/2014)... News) -- Stress can slow a woman,s metabolism and lead ... 58 women, average age 53, who were asked about their ... than included 930 calories and 60 grams of fat. The ... women to burn off those calories and fat. On ... the previous 24 hours burned 104 fewer calories in the ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... Ultra performance liquid chromatography or UPLC is ... of liquid chromatography that involves the use ... conditions to separate chromatographic compounds. This highly ... faster detection and analysis of chromatography samples. ...
(Date:7/14/2014)... Atlanta, GA (PRWEB) July 14, 2014 ... networking and relationship-marketing firm, announced today that nominations ... for the 2014 Information Security Executive® (ISE®) North ... Security Executive® of the Year, which recognizes executives ... organizations through risk management, data-asset protection, regulatory compliance, ...
Breaking Medicine News(10 mins):Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Stress May Leave You Heading to the Cookie Jar 2Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3
... Teriparatide may help asthma patients avoid fracture, researchers ... A new drug has proven superior to standard ... treatment, researchers say. , Glucocorticoid medicines such as ... disorders, skin allergies and other conditions, researchers note. ...
... suspect it may cause airway inflammation, , , WEDNESDAY, Nov. 14 ... to help protect the airways now appears to be a ... a role in the development of asthma, according to new ... New England Journal of Medicine , Yale University researchers ...
... Researchers at the Medical College of Wisconsin in Milwaukee ... normal tissue after exposure may be reduced by a ... in the on line issue of the International Journal ... that long-term administration of the drug captopril, starting at ...
... data on worldwide cancer incidence, researchers at the Moores ... have shown a clear association between deficiency in exposure ... , UVB exposure triggers photosynthesis of vitamin D3 ... also available through diet and supplements. Previous studies from ...
... scientists say , , WEDNESDAY, Nov. 14 (HealthDay News) -- ... Alzheimer,s diagnosis than white patients, a new study suggests. ... Indian descent diagnosed with the disease were found to ... patients, patients of Hispanic or black ethnicity were ...
... 14 Biodel Inc. (Nasdaq:,BIOD) today announced that ... Financial Officer, Vice President of Corporate Development,and Treasurer, ... to welcome Gerard to our team," said Dr. ... in executing,complex financial transactions and negotiating marketing partnerships ...
Cached Medicine News:Health News:New Drug Fights Medication-Linked Bone Loss 2Health News:Defensive Protein Linked to Asthma 2Health News:Defensive Protein Linked to Asthma 3Health News:Medical College of Wisconsin study finds drug may limit radiation kidney damage in BMT patients 2Health News:Global view shows link between endometrial cancer and vitamin D status 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 3Health News:Blacks, Hispanics Live Longer With Alzheimer's 4Health News:Biodel Inc. Announces Appointment of Gerard Michel as CFO, VP of Corporate Development and Treasurer 2Health News:Biodel Inc. Announces Appointment of Gerard Michel as CFO, VP of Corporate Development and Treasurer 3
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... are used by hospitals, clinics and the ... health conditions. The majority of these products ... are offered in strip, cassette, and stick ... membrane tests are also available. All require ...
... The CALBIOTECH INC. (CBI) Prolactin ELISA ... of prolactin in human serum or plasma. ... chain polypeptide hormone with a molecular weight ... is based on a solid phase direct ...
... is a polypeptide hormone secreted in significant ... the placenta. Prolactin, in synergy with estrogen, ... initiation and maintenance of mammary gland growth ... prolactin may have effects on cell growth ...
Medicine Products: